Using MRI scans to personalize radiotherapy for high grade glioma
Serial Advanced Magnetic Resonance Imaging (MRI) for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
This study tests if using regular MRI scans to track tumor changes can help doctors personalize radiation treatment for patients with high grade glioma to improve their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT04771806 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of repeated magnetic resonance imaging (MRI) scans in monitoring tumor changes during radiation and chemotherapy for patients with high grade glioma. It aims to compare the dosimetric coverage of the tumor using immediate post-operative MRI versus newly acquired MRI before radiation therapy. Additionally, the study evaluates the relationship between MRI findings and tumor progression, neurocognitive function, and overall survival. By adapting treatment plans based on serial MRI data, the study seeks to improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed high grade glioma and a Karnofsky performance status of 60 or higher.
Not a fit: Patients who are unable to undergo MRI scans or have lower performance status may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for patients with high grade glioma.
How similar studies have performed: Other studies have shown promise in using adaptive radiotherapy approaches, but this specific methodology is novel in its focus on serial MRI for high grade glioma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with histologic confirmation of high grade glioma * Patients must be age \>= 18 years * Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol, and has been approved and amended by the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB) * Patients must have Karnofsky performance status (KPS) \>= 60 * Patients must be able to obtain an MRI scan with gadolinium contrast * Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breastfeeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Female patients who consent to participate in the study will need to use contraceptive methods for the duration of the study
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Caroline Chung — M.D. Anderson Cancer Center
- Study coordinator: Caroline Chung
- Email: cchung3@mdanderson.org
- Phone: 713-563-2300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.